135 related articles for article (PubMed ID: 3741536)
1. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
2. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
[TBL] [Abstract][Full Text] [Related]
3. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
4. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
6. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
7. The bioavailability of two commercial preparations of allopurinol tablets.
Marcus M; Tse FL; Kleinberg SI
Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):302-5. PubMed ID: 7107081
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of allopurinol oral and rectal dosage forms.
Chang SL; Kramer WG; Feldman S; Ballentine R; Frankel LS
Am J Hosp Pharm; 1981 Mar; 38(3):365-8. PubMed ID: 7223751
[TBL] [Abstract][Full Text] [Related]
9. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
[TBL] [Abstract][Full Text] [Related]
10. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
11. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
12. [The bioequivalence of a new allopurinol tablet formulation in comparison to a reference formulation].
Metzner JE; Buchberger D; Läuter J; Pech R
Arzneimittelforschung; 1997 Nov; 47(11):1236-41. PubMed ID: 9463301
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations (author's transl)].
Jaeger H; Russmann D; Rasper J; Blome J
Arzneimittelforschung; 1982; 32(4):438-43. PubMed ID: 6896646
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
Lach HJ; Bader B; Schnitker J; Harries EH
Arzneimittelforschung; 1982; 32(1):76-9. PubMed ID: 7199345
[TBL] [Abstract][Full Text] [Related]
15. [A new and quick method for determination of allopurinol and oxipurinol in serum (author's transl)].
Nitsche V; Mascher H
Arzneimittelforschung; 1980; 30(11):1855-7. PubMed ID: 7192993
[TBL] [Abstract][Full Text] [Related]
16. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of allopurinol-containing tablet preparations.
Barthel W; Hüller G; Haustein KO
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):148-52. PubMed ID: 10190763
[TBL] [Abstract][Full Text] [Related]
19. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
[TBL] [Abstract][Full Text] [Related]
20. Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M
Am J Vet Res; 1997 May; 58(5):511-5. PubMed ID: 9140560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
